We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Programmes would use smallpox vaccine and immunise close contacts of confirmed cases
Industry says it will reserve production capacity for low- income nations for a fee if border bans are ended
JCVI’s provisional guidance limits top-up jabs to over-65s, frontline health workers and vulnerable younger people
Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting
Top finance director ousted after one day in job following emergence of probe at former employer
Exit of Jorge Gomez after only a day in the job is latest in string of executives to leave biotech group
Jorge Gomez leaves vaccine maker after former employer launches probe into financial reporting
Pharma group’s chief is right to take advantage of the market sell-off to boost pipeline
US pharmaceutical group’s biggest deal in more than 5 years comes as sales of its Covid vaccine are set to fall
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
US drugmaker says demand for ‘bivalent booster’ could lift jab sales in second half of 2022
Vulnerable people feel they are forgotten because of government’s ‘living with Covid’ strategy
US biotech to dismantle sales infrastructure for treatment as it begins search for successor
On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets
Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings
Tishman Speyer, Bellco and Brookfield among those increasing their bets on expanding life sciences
Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker
While tech still features prominently on the latest annual FT ranking, pharmaceuticals and health account for half the top 10
Congressional probe found 22 consultants had advised both the US FDA and drug manufacturers over a decade
Two top-10 shareholders say distribution problems not supply is reason for slower vaccination rates in low-income countries
Private equity giant teams up with India’s largest company in attempt to buy UK pharmacy chain
UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’
The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy
Rout revives fears of American buyers swooping on the continent’s start-ups
‘There has been a change in attitudes. There are a lot of initiatives that were not foreseen a couple of years ago’
International Edition
